{"id":71855,"date":"2026-08-06T15:10:16","date_gmt":"2026-08-06T07:10:16","guid":{"rendered":"https:\/\/flcube.com\/?p=71855"},"modified":"2026-08-06T15:10:17","modified_gmt":"2026-08-06T07:10:17","slug":"astellas-reports-record-q1-fy2026-revenue-of-%c2%a5640-9b-driven-by-strategic-brands-growth-and-raises-full-year-outlook","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71855","title":{"rendered":"Astellas Reports Record Q1 FY2026 Revenue of \u00a5640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Astellas Pharma Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/4503:TYO\">TYO: 4503<\/a>) announced <strong>first-quarter fiscal year 2026 financial results<\/strong> featuring <strong>revenue of 640.914 billion yen<\/strong> (approximately <strong>USD 4.066 billion<\/strong>), representing a <strong>26.7% year-over-year increase<\/strong>. The exceptional performance was primarily driven by <strong>strategic brands revenue of 160.3 billion yen<\/strong>, up <strong>43.2% year-over-year<\/strong>, led by <strong>Padcev, Izervay, Vyloy, Veozah, and Xospata<\/strong>. The company maintained its <strong>full fiscal year 2026 revenue forecast at 2,220.0 billion yen<\/strong> (+3.8% YoY) with <strong>core operating profit projected at 460.0 billion yen<\/strong> (+8.4% YoY).<\/p>\n\n\n\n<h2 id=\"h-financial-highlights-q1-fy2026\" class=\"wp-block-heading\">Financial Highlights | Q1 FY2026<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q1 FY2026 Result<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>\u00a5640.914 billion<\/td><td>+26.7%<\/td><\/tr><tr><td><strong>Strategic Brands Revenue<\/strong><\/td><td>\u00a5160.3 billion<\/td><td>+43.2%<\/td><\/tr><tr><td><strong>Full-Year Revenue Forecast<\/strong><\/td><td>\u00a52,220.0 billion<\/td><td>+3.8%<\/td><\/tr><tr><td><strong>Full-Year Core Operating Profit<\/strong><\/td><td>\u00a5460.0 billion<\/td><td>+8.4%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-brands-portfolio-performance\" class=\"wp-block-heading\">Strategic Brands Portfolio Performance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Padcev<\/strong>: Continued strong growth in bladder cancer indication<\/li>\n\n\n\n<li><strong>Izervay<\/strong>: Robust uptake in geographic atrophy treatment<\/li>\n\n\n\n<li><strong>Vyloy<\/strong>: Emerging performance in targeted oncology segment<\/li>\n\n\n\n<li><strong>Veozah<\/strong>: Growing adoption for menopausal vasomotor symptoms<\/li>\n\n\n\n<li><strong>Xospata<\/strong>: Sustained performance in FLT3-mutated AML<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>43.2% year-over-year growth<\/strong> in strategic brands demonstrates successful commercial execution and market penetration across diverse therapeutic areas including oncology, ophthalmology, women&#8217;s health, and hematology.<\/p>\n\n\n\n<h2 id=\"h-geographic-revenue-analysis-q1-fy2026\" class=\"wp-block-heading\">Geographic Revenue Analysis | Q1 FY2026<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Revenue (\u00a5 billion)<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>288.8<\/td><td>+28.5%<\/td><\/tr><tr><td><strong>Japan<\/strong><\/td><td>79.6<\/td><td>+15.5%<\/td><\/tr><tr><td><strong>Established Markets<\/strong> (Europe, Canada, etc.)<\/td><td>152.2<\/td><td>+18.2%<\/td><\/tr><tr><td><strong>China<\/strong> (Mainland China and Hong Kong)<\/td><td>32.1<\/td><td>+8.9%<\/td><\/tr><tr><td><strong>Other Markets<\/strong><\/td><td>85.4<\/td><td>+60.5%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-regional-insights\" class=\"wp-block-heading\">Regional Insights<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>United States<\/strong>: Remains largest market with <strong>288.8 billion yen<\/strong> (+28.5%), driven by strategic brands adoption<\/li>\n\n\n\n<li><strong>Other Markets<\/strong>: Exceptional <strong>60.5% growth<\/strong> reflects successful expansion into emerging markets<\/li>\n\n\n\n<li><strong>China<\/strong>: Modest <strong>8.9% growth<\/strong> to <strong>32.1 billion yen<\/strong>, indicating continued market development challenges<\/li>\n\n\n\n<li><strong>Global Diversification<\/strong>: Balanced geographic portfolio reduces regional dependency risks<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-full-year-fy2026-guidance\" class=\"wp-block-heading\">Full-Year FY2026 Guidance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>FY2026 Forecast<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>\u00a52,220.0 billion<\/td><td>+3.8%<\/td><\/tr><tr><td><strong>Core Operating Profit<\/strong><\/td><td>\u00a5460.0 billion<\/td><td>+8.4%<\/td><\/tr><tr><td><strong>Operating Margin<\/strong><\/td><td>~20.7%<\/td><td>Expansion vs. prior year<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The maintained guidance reflects confidence in sustained strategic brands momentum while accounting for potential foreign exchange headwinds and competitive pressures in mature markets.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<h3 id=\"h-commercial-excellence\" class=\"wp-block-heading\">Commercial Excellence<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Transformation<\/strong>: Successful transition from legacy products to high-growth strategic brands<\/li>\n\n\n\n<li><strong>Therapeutic Diversification<\/strong>: Balanced portfolio across oncology, ophthalmology, women&#8217;s health, and rare diseases<\/li>\n\n\n\n<li><strong>Pricing Power<\/strong>: Premium positioning of innovative therapies supporting margin expansion<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-geographic-strategy\" class=\"wp-block-heading\">Geographic Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>US Focus<\/strong>: Continued investment in largest and most profitable market<\/li>\n\n\n\n<li><strong>Emerging Markets<\/strong>: Exceptional growth in &#8220;Other Markets&#8221; category validates expansion strategy<\/li>\n\n\n\n<li><strong>China Positioning<\/strong>: Modest growth suggests cautious approach amid regulatory and pricing pressures<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-financial-discipline\" class=\"wp-block-heading\">Financial Discipline<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Profit Leverage<\/strong>: Core operating profit growth (+8.4%) outpacing revenue growth (+3.8%) demonstrates operational efficiency<\/li>\n\n\n\n<li><strong>Cash Generation<\/strong>: Strong profitability supports pipeline investment and shareholder returns<\/li>\n\n\n\n<li><strong>Strategic Flexibility<\/strong>: Robust financial position enables continued business development activities<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The Q1 FY2026 results validate Astellas&#8217; strategic transformation into a focused, innovation-driven pharmaceutical company with a diversified global footprint and premium therapeutic portfolio.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, product sales, and business outlook. Actual results may differ materially due to competitive pressures, regulatory developments, foreign exchange fluctuations, and macroeconomic conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1q2026_en.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 1q2026_en.\"><\/object><a id=\"wp-block-file--media-a074fce4-a86a-461b-b741-1b11d5d11eca\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1q2026_en.pdf\">1q2026_en<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1q2026_en.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a074fce4-a86a-461b-b741-1b11d5d11eca\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Astellas Pharma Inc. (TYO: 4503) announced first-quarter fiscal year 2026 financial results featuring revenue of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":71859,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[353,27,1177],"class_list":["post-71855","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-astellas-pharma","tag-finanical-reports","tag-tyo-4503"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Astellas Reports Record Q1 FY2026 Revenue of \u00a5640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Astellas Pharma Inc. (TYO: 4503) announced first-quarter fiscal year 2026 financial results featuring revenue of 640.914 billion yen (approximately USD 4.066 billion), representing a 26.7% year-over-year increase. The exceptional performance was primarily driven by strategic brands revenue of 160.3 billion yen, up 43.2% year-over-year, led by Padcev, Izervay, Vyloy, Veozah, and Xospata. The company maintained its full fiscal year 2026 revenue forecast at 2,220.0 billion yen (+3.8% YoY) with core operating profit projected at 460.0 billion yen (+8.4% YoY).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71855\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astellas Reports Record Q1 FY2026 Revenue of \u00a5640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook\" \/>\n<meta property=\"og:description\" content=\"Astellas Pharma Inc. (TYO: 4503) announced first-quarter fiscal year 2026 financial results featuring revenue of 640.914 billion yen (approximately USD 4.066 billion), representing a 26.7% year-over-year increase. The exceptional performance was primarily driven by strategic brands revenue of 160.3 billion yen, up 43.2% year-over-year, led by Padcev, Izervay, Vyloy, Veozah, and Xospata. The company maintained its full fiscal year 2026 revenue forecast at 2,220.0 billion yen (+3.8% YoY) with core operating profit projected at 460.0 billion yen (+8.4% YoY).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71855\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-06T07:10:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-06T07:10:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0604.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71855#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71855\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Astellas Reports Record Q1 FY2026 Revenue of \u00a5640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook\",\"datePublished\":\"2026-08-06T07:10:16+00:00\",\"dateModified\":\"2026-08-06T07:10:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71855\"},\"wordCount\":460,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71855#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0604.webp\",\"keywords\":[\"Astellas Pharma\",\"Finanical Reports\",\"TYO: 4503\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71855#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71855\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71855\",\"name\":\"Astellas Reports Record Q1 FY2026 Revenue of \u00a5640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71855#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71855#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0604.webp\",\"datePublished\":\"2026-08-06T07:10:16+00:00\",\"dateModified\":\"2026-08-06T07:10:17+00:00\",\"description\":\"Astellas Pharma Inc. (TYO: 4503) announced first-quarter fiscal year 2026 financial results featuring revenue of 640.914 billion yen (approximately USD 4.066 billion), representing a 26.7% year-over-year increase. The exceptional performance was primarily driven by strategic brands revenue of 160.3 billion yen, up 43.2% year-over-year, led by Padcev, Izervay, Vyloy, Veozah, and Xospata. The company maintained its full fiscal year 2026 revenue forecast at 2,220.0 billion yen (+3.8% YoY) with core operating profit projected at 460.0 billion yen (+8.4% YoY).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71855#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71855\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71855#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0604.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0604.webp\",\"width\":1080,\"height\":608,\"caption\":\"Astellas Reports Record Q1 FY2026 Revenue of \u00a5640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71855#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Astellas Reports Record Q1 FY2026 Revenue of \u00a5640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Astellas Reports Record Q1 FY2026 Revenue of \u00a5640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook - Insight, China&#039;s Pharmaceutical Industry","description":"Astellas Pharma Inc. (TYO: 4503) announced first-quarter fiscal year 2026 financial results featuring revenue of 640.914 billion yen (approximately USD 4.066 billion), representing a 26.7% year-over-year increase. The exceptional performance was primarily driven by strategic brands revenue of 160.3 billion yen, up 43.2% year-over-year, led by Padcev, Izervay, Vyloy, Veozah, and Xospata. The company maintained its full fiscal year 2026 revenue forecast at 2,220.0 billion yen (+3.8% YoY) with core operating profit projected at 460.0 billion yen (+8.4% YoY).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71855","og_locale":"en_US","og_type":"article","og_title":"Astellas Reports Record Q1 FY2026 Revenue of \u00a5640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook","og_description":"Astellas Pharma Inc. (TYO: 4503) announced first-quarter fiscal year 2026 financial results featuring revenue of 640.914 billion yen (approximately USD 4.066 billion), representing a 26.7% year-over-year increase. The exceptional performance was primarily driven by strategic brands revenue of 160.3 billion yen, up 43.2% year-over-year, led by Padcev, Izervay, Vyloy, Veozah, and Xospata. The company maintained its full fiscal year 2026 revenue forecast at 2,220.0 billion yen (+3.8% YoY) with core operating profit projected at 460.0 billion yen (+8.4% YoY).","og_url":"https:\/\/flcube.com\/?p=71855","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-06T07:10:16+00:00","article_modified_time":"2026-08-06T07:10:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0604.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71855#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71855"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Astellas Reports Record Q1 FY2026 Revenue of \u00a5640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook","datePublished":"2026-08-06T07:10:16+00:00","dateModified":"2026-08-06T07:10:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71855"},"wordCount":460,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=71855#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0604.webp","keywords":["Astellas Pharma","Finanical Reports","TYO: 4503"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71855#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71855","url":"https:\/\/flcube.com\/?p=71855","name":"Astellas Reports Record Q1 FY2026 Revenue of \u00a5640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=71855#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=71855#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0604.webp","datePublished":"2026-08-06T07:10:16+00:00","dateModified":"2026-08-06T07:10:17+00:00","description":"Astellas Pharma Inc. (TYO: 4503) announced first-quarter fiscal year 2026 financial results featuring revenue of 640.914 billion yen (approximately USD 4.066 billion), representing a 26.7% year-over-year increase. The exceptional performance was primarily driven by strategic brands revenue of 160.3 billion yen, up 43.2% year-over-year, led by Padcev, Izervay, Vyloy, Veozah, and Xospata. The company maintained its full fiscal year 2026 revenue forecast at 2,220.0 billion yen (+3.8% YoY) with core operating profit projected at 460.0 billion yen (+8.4% YoY).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71855#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71855"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=71855#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0604.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0604.webp","width":1080,"height":608,"caption":"Astellas Reports Record Q1 FY2026 Revenue of \u00a5640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71855#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Astellas Reports Record Q1 FY2026 Revenue of \u00a5640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0604.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71855"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71855\/revisions"}],"predecessor-version":[{"id":71860,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71855\/revisions\/71860"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/71859"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71855"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}